Clinical Trials Sponsored by Ecogene 21

Total 1192 results

Hellenic Cooperative Oncology Group
Eli Lilly and Company; Celgene Corporation

Completed

RAmucirumab Combined wIth Standard Nab-paclitaxel and Gemcitabine as First-line Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma (RACING)

Pancreatic Adenocarcinoma

Greece
National Institute of Allergy and Infectious Diseases...
Celgene Corporation

Completed

A Phase I, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Thalidomide in Subjects With HIV-1 Infection

HIV Infections

United States
Memorial Sloan Kettering Cancer Center
Celgene Corporation; Miami Cancer Institute

Completed

Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers

Lung Cancer | Untreated Stage IV or Recurrent Squamous Cell Lung Cancers

United States
Ohio State University Comprehensive Cancer Center
Genentech, Inc.; Celgene Corporation

Completed

Phase II NCT (Neoadjuvant Chemotherapy) w/ Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast Cancer

Breast Cancer

United States
Matthew Galsky
Celgene

Terminated

Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma

Bladder Cancer

United States
University of Michigan Rogel Cancer Center
Celgene; Onyx Therapeutics, Inc.

Completed

Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma

Multiple Myeloma

United States
PETHEMA Foundation
Celgene; Janssen-Cilag Ltd.; TFS Trial Form Support

Completed

Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone

Multiple Myeloma

Spain
H. Lee Moffitt Cancer Center and Research Institute
Celgene Corporation

Completed

Pre-Transplant 5-Azacitidine In Patients With High-Risk Myelodysplastic Syndrome Who Are Candidates For Allogeneic Hematopoietic Cell Transplant

Leukemia

United States
H. Lee Moffitt Cancer Center and Research Institute
Celgene Corporation

Completed

Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia (AML) in CR After Induction Chemotherapy

Leukemia

United States
The Christie NHS Foundation Trust
Celgene Corporation; Leukemia Research Fund

Terminated

RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial (RESPeCT)

Chronic Lymphocytic Leukaemia

United Kingdom
OHSU Knight Cancer Institute
Oregon Health and Science University; Celgene Corporation

Recruiting

Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System

Metastatic Malignant Neoplasm in the Brain | Central Nervous System Neoplasm | Cranial Nerve Disorder

United States
M.D. Anderson Cancer Center
Celgene Corporation; The Leukemia and Lymphoma Society

Completed

Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma

Leukemia

United States
University of Birmingham
Merck Sharp & Dohme LLC; Celgene; Leukemia Research Fund

Completed

Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS (RAvVA)

Leukemia, Myeloid, Acute

United Kingdom
H. Lee Moffitt Cancer Center and Research Institute
Novartis; Celgene Corporation

Completed

Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Academisch Medisch Centrum - Universiteit van Amsterdam...
Novartis; Celgene Corporation

Completed

Phase I/II Study of LDE225 With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer (MATRIX)

Pancreatic Cancer

Netherlands
Ajai Chari
Celgene Corporation

Completed

Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

United States
David Rizzieri, MD
Genzyme, a Sanofi Company; Celgene Corporation

Completed

Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)

Leukemia, Lymphocytic, Chronic, B-Cell

United States
Memorial Sloan Kettering Cancer Center
Celgene Corporation; National Comprehensive Cancer Network

Completed

Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)

HEAD & NECK Cancer

United States
International Myeloma Foundation
Janssen Scientific Affairs, LLC; Celgene; Amgen; Trevie, Inc.

Active, not recruiting

Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant (ASCENT)

Smoldering Multiple Myeloma

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis; Celgene Corporation

Active, not recruiting

Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Joseph Tuscano
National Cancer Institute (NCI); Celgene

Active, not recruiting

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Hairy Cell Leukemia | Refractory Mantle Cell Lymphoma | Recurrent... and other conditions

United States
Ohio State University Comprehensive Cancer Center
Millennium Pharmaceuticals, Inc.; Celgene Corporation

Completed

Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
Dana-Farber Cancer Institute
National Cancer Institute (NCI); Celgene; Schering-Plough

Completed

Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma

Brain and Central Nervous System Tumors

United States
Weill Medical College of Cornell University
Merck Sharp & Dohme LLC; Celgene

Completed

Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL)

Lymphoma

United States
Steven P. Treon, MD, PhD
Celgene Corporation

Terminated

Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia

Waldenstrom's Macroglobulinemia

United States
Massachusetts General Hospital
Bristol-Myers Squibb; Celgene; Multiple Myeloma Research Consortium

Active, not recruiting

A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

Multiple Myeloma

United States
Beth Christian
Genentech, Inc.; Celgene

Active, not recruiting

Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Recurrent Marginal Zone Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Burkitt Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Refractory Burkitt Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma and other conditions

United States
Alliance Foundation Trials, LLC.
Takeda; Janssen Scientific Affairs, LLC; Celgene Corporation

Active, not recruiting

Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM

Myeloma, Multiple

United States
Heinrich-Heine University, Duesseldorf
Celgene Corporation; Koordinierungszentrum für Klinische Studien Düsseldorf

Active, not recruiting

IDH2-Post-Allo-Trial for Patients With IDH2-mut Myeloid Neoplasms After Allo-SCT

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Chronic Myelomonocytic Leukemia | IDH2 Gene Mutation | IDH2 R172 | IDH2 R140

Germany
OHSU Knight Cancer Institute
Oregon Health and Science University; Celgene Corporation

Completed

Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

Pancreatic Adenocarcinoma | Resectable Pancreatic Carcinoma

United States
Ciusss de L'Est de l'Île de Montréal
Celgene; C3i Center Inc.

Active, not recruiting

Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant

Multiple Myeloma | Relapsed Hematologic Malignancy

Canada
Massachusetts General Hospital
Dana-Farber Cancer Institute; Genentech, Inc.; Celgene Corporation

Completed

Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States
Groupe Oncologie Radiotherapie Tete et Cou
UNICANCER; Center Eugene Marquis

Active, not recruiting

Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHN (REWRITe)

HNSCC

France
Rutgers, The State University of New Jersey
Natera, Inc.; BioGene Pharmaceutical Ltd.

Recruiting

Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma

Carcinoma, Hepatocellular | Liver Cell Carcinoma

United States
Spanish Breast Cancer Research Group
Novartis; Pfizer; Hoffmann-La Roche; AstraZeneca; Celgene

Recruiting

A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC) (REGISTEM)

Breast Neoplasms

Spain
Sidney Kimmel Comprehensive Cancer Center at Johns...
Celgene; Aduro Biotech, Inc.

Active, not recruiting

Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission

Multiple Myeloma

United States
Raija Silvennoinen
Takeda; Celgene; Nordic Myeloma Study Group

Active, not recruiting

Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients

Multiple Myeloma

Norway, Sweden, Finland, Lithuania
Priyanka Sharma
Bristol-Myers Squibb; Celgene Corporation

Active, not recruiting

Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

Breast Cancer | Triple-Negative Breast Cancer

United States
University of Pennsylvania
National Heart, Lung, and Blood Institute (NHLBI); Celgene Corporation

Completed

Vascular Inflammation in Psoriasis - Apremilast (VIP-A)

Cardiovascular Diseases | Psoriasis

United States
Lynn E. Spitler, MD
Genentech, Inc.; Celgene Corporation

Completed

Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study (AbraxAvast)

Metastatic Malignant Melanoma

United States
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center; Celgene; Incyte Corporation

Active, not recruiting

A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis

Myelofibrosis

United States
Al B. Benson, III, MD
Celgene Corporation; Big Ten Cancer Research Consortium

Completed

FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma

Gastric Cancer | Gastro-Esophageal Junction Adenocarcinoma

United States
Asociación de Oncología Médica del Hospital de...
Celgene; Apices Soluciones S.L.

Completed

Nab-paclitaxel and Gemcitabine, in Elderly Patients Untreated Metastatic Pancreatic Adenocarcinoma

Pancreatic Carcinoma Metastatic

Spain
Northwestern University
National Cancer Institute (NCI); Celgene; The Leukemia and Lymphoma Society

Withdrawn

Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase

United States
University Hospital, Toulouse
Dana-Farber Cancer Institute; Celgene Corporation; Janssen-Cilag Ltd.

Completed

Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years (IFM/DFCI2009)

Myeloma

France
Sidney Kimmel Cancer Center at Thomas Jefferson...
Celgene

Withdrawn

Patient Derived Cancer Cell Lines in Identifying Molecular Changes in Patients With Previously Untreated Pancreatic Cancer Receiving Gemcitabine Hydrochloride-Based Chemotherapy

Pancreatic Ductal Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer

United States
Ohio State University Comprehensive Cancer Center
Celgene Corporation; National Comprehensive Cancer Network

Completed

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery

Intraocular Melanoma

United States
University of California, San Diego
Celgene; The Organization of Teratology Information Specialists

Active, not recruiting

Apremilast Pregnancy Exposure Registry

Psoriasis | Psoriatic Arthritis

United States
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH); Celgene

Active, not recruiting

Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer

Resectable Cholangiocarcinoma | Stage IB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage II Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Celgene Corporation

Completed

Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma

Refractory/Relapsed Indolent Non-Hodgkin Lymphoma

United States

Clinical Trials Sponsored by Ecogene 21

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations